共 88 条
[1]
Gupta K(2008)Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review Cancer Treatment Reviews 34 193-205
[2]
Miller JD(1987)A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone The New England Journal of Medicine 316 889-897
[3]
Li JZ(2011)Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence The Oncologist 16 14-22
[4]
Russell MW(2012)Emerging immunotherapies for renal cell carcinoma Annals of oncology 23 viii35-viii40
[5]
Charbonneau C(2007)Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma Acta Medica 50 207-212
[6]
Rosenberg SA(2013)Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Cancer Journal 19 353-364
[7]
Lotze MT(2008)Cytokines and their relationship to the symptoms and outcome of cancer Nature Reviews Cancer 8 887-899
[8]
Muul LM(2006)Interferons, immunity and cancer immunoediting Nature Reviews Immunology 6 836-848
[9]
Hutson TE(2000)IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells Journal of Immunology 164 231-239
[10]
Escudier B(2011)Chemosensitization of tumors by resveratrol Annals of the New York Academy of Sciences 1215 150-160